InflaRx N.V.
IFRX Healthcare Biotechnology
In the quarter to June 2026, revenue fell 128.9%, EPS grew 54.2% and free cash flow grew 69.3%, each against the same quarter a year earlier.
Follow IFRX
InflaRx N.V. (IFRX) EV/Sales
As of 16 October 2026, InflaRx N.V. (IFRX) trades at a EV/Sales of −1,061×. Over the past ten years it has ranged from −1,061× (October 2026) to 4,846× (May 2026) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 411× | (10.96%) |
| FY2024 | 462× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 411× | 172.54% |
| Sep 2025 | 151× | — |
| Jun 2025 | −41.2× | — |
| Dec 2024 | 462× | 221.81% |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IFRX InflaRx N.V. | −1,061× |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| MGNX MacroGenics, Inc. compare | 0.2× |
| PLX Protalix BioTherapeutics, Inc. compare | 2.3× |
| ALEC Alector, Inc. compare | 3.6× |
| CAMP CAMP4 Therapeutics Corporation compare | 22.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)